Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Real-time Quote. Real-time Tradegate - 05/30 09:11:45 am
61.575 EUR   -0.02%
05/29 UCB : Transparency notification
05/22 UCB : and Amgen announce top-line phase 3 data from …
05/17 UCB : Transparency notification
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UCB : Transparency notification of Vanguard Health Care Fund

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2012 | 08:41pm CEST

Participation on March 30, 2012 (according to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).

Brussels (Belgium), April 11, 2012 - 7.30 p.m. (CET) - regulated information - Vanguard Health Care Fund (having its registered offices c/o The Vanguard Group, 455 Devon Park Drive, Wayne, PA 19087 - USA) acquired 5,821,811 UCB shares with voting rights (on a total number of 183,365,052) on March 30, 2012, representing 3.17% of UCB's share capital, which means that Vanguard Health Care Fund crossed the threshold of notification of 3%.

UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608


For further information

Antje Witte, Investor Relations, UCB

T +32.2.559.9414, [email protected]

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
05/29 UCB : Transparency notification
05/22 UCB : and Amgen announce top-line phase 3 data from …
05/17 UCB : Transparency notification
05/04 Attention Deficit Hyperactivity Disorder ADHD Drug Sales Market 2017 - Shire,..
04/28 UCB : ex-dividend day for annual dividend
04/27 UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol) dose &hell..
04/24 UCB FIRST THREE MONTHS INTERIM REPOR :  UCB with …
04/20 UCB : Findings from UCB S.A. Provides New Data on Epilepsy (Health care cost ass..
04/19UCB SA : quaterly earnings release
More news
Sector news : Pharmaceuticals - NEC
05/29 WARREN BUFFETT : Warren Buffett takes 3 percent stake in Germany's Lanxess
05/29DJMERCK : Congo Approves Anti-Ebola Vaccine to Combat Outbreak in Remote Northeast
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/22 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
02/24 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q4 2016 Results - Earnings Call ..
02/23 UCB S.A. reports FY results
Advertisement
Financials (€)
Sales 2017 4 299 M
EBIT 2017 920 M
Net income 2017 594 M
Debt 2017 551 M
Yield 2017 1,94%
P/E ratio 2017 18,63
P/E ratio 2018 15,68
EV / Sales 2017 2,91x
EV / Sales 2018 2,65x
Capitalization 11 980 M
More Financials
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 68,1 €
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Ismail Kola Chief Scientific Officer, EVP & Head-New Medicines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB1.12%13 316
JOHNSON & JOHNSON10.16%341 901
ROCHE HOLDING LTD.14.62%235 172
NOVARTIS AG6.07%210 841
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results